Sanofi: completes acquisition of Protein Science.
(CercleFinance.com) - Sanofi has announced that it has finalised the acquisition of Protein Sciences, a biotechnology company based in Meriden, in the US State of Connecticut, following the approval of the FTC (Federal Trade Commission).
Thanks to this acquisition, Sanofi Pasteur, Sanofi's global vaccines entity adds Flublok (influenza vaccine) to its portfolio, which is the only flu vaccine made from recombinant proteins that is approved by the US Food and Drug Administration (FDA).
The acquisition of Protein Sciences fits with Sanofi Pasteur's strategic initiative to explore non-egg-based influenza vaccine manufacturing technologies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Thanks to this acquisition, Sanofi Pasteur, Sanofi's global vaccines entity adds Flublok (influenza vaccine) to its portfolio, which is the only flu vaccine made from recombinant proteins that is approved by the US Food and Drug Administration (FDA).
The acquisition of Protein Sciences fits with Sanofi Pasteur's strategic initiative to explore non-egg-based influenza vaccine manufacturing technologies.
Copyright (c) 2017 CercleFinance.com. All rights reserved.